At a glance
- Originator Merck & Co
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 18 Mar 1999 Preclinical development for Inflammation in USA (Unknown route)